Tiglutik (riluzole) Oral Suspension 50 mg/10 mL (5 mg/mL), 600 mL (two bottles/300 mL each), RX only, Manufactured for ITF Pharma, Inc., Berwyn, PA 19312 USA NDC:70726-0303-1 (carton) and 70726-0303-2 (bottle)
Published November 29, 2023 · Recall initiated: October 20, 2023
Summary
FDA records drug Class II recall D-0115-2024, published November 29, 2023 and initiated October 20, 2023. Recalling firm: ITF PHARMA INC; Status: Terminated; Reported quantity: 1,792 bottles; Lot: LOT# 2231901, Exp. 11/30/2025; 2307901, Exp. 03/31/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Viscosity Specifications: Out-of-specification test results for viscosity
What to do
Voluntary: Firm initiated · Letter
Get an email if TIGLUTIK has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- TIGLUTIK
- Manufacturer
- ITF PHARMA INC
- Distributor
- Distributed to one distributor in TN who may have further distributed.
- Lot
- LOT# 2231901, Exp. 11/30/2025; 2307901, Exp. 03/31/2026
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDALisinopril Tablets USP 20 mg, packaged in a) 15-count blister card (NDC 0615-7718-05), b) 30-count blisterNovember 29, 2023
- FDA8.4% Sodium Bicarbonate Injection, USP, 50 mEq/50 mL (1mEq/mL), a) 20x50 mL Single Dose Vials (Vial NDCNovember 29, 2023
- FDABuspirone Hydrochloride Tabs USP 10 mg, packaged in a) 15-count blister card (NDC 0615-7718-05) b) 30-countNovember 29, 2023
- FDAMidazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL (1mg/mL), 100 mL Single-Dose Vial, 25 count carton,November 29, 2023
- FDAEsomeprazole Magnesium Delayed-Release Capsules, USP 20mg, Packaged as (a) 30-count bottle, NDC 68462-390-30;November 29, 2023
- FDAELCYS (cysteine hydrochloride injection), USP, 500 mg/10mL (50 mg/mL), 10x10 mL Single Dose Sterile Vials, ForNovember 29, 2023
Questions about this recall
Was Tiglutik (riluzole) Oral Suspension 50 mg/10 mL (5 mg/mL), 600 mL (two bottles/300 mL each), RX only, Manufactured for ITF Pharma, Inc., Berwyn, PA 19312 USA NDC:70726-0303-1 (carton) and 70726-0303-2 (bottle) recalled?
Yes. FDA published recall D-0115-2024 on November 29, 2023. Reported hazard: Failed Viscosity Specifications: Out-of-specification test results for viscosity
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: TIGLUTIK.